|Fungi and Disease|
Blastomycosis: The great pretender can also be an opportunist. Initial clinical diagnosis and underlying diseases in 123 patients.
Lemos LB, Baliga M, Guo M. Department of Pathology, University of Texas, Houston; and the Department of Pathology, University of Mississippi, Jackson. Ann Diagn Pathol 2002 Jun;6(3):194-203
Clinically, blastomycosis can be difficult to recognize even in the endemic areas where clinicians are aware of this problem. In only 18% of 123 patients from the University of Mississippi Medical Center (Jackson, MS) blastomycosis was correctly suspected at the initial patient evaluation. Pneumonia (40%), malignant tumors (16%), and tuberculosis (14%) were the most common misdiagnoses. The false first impression frequently resulted in unnecessary surgeries or treatment delays, with patients receiving inefficient antibiotic therapy for months. The presence of cutaneous involvement by the disease makes its' recognition easier for the clinician, raising the percentage of correct initial diagnosis to 64%. To evaluate the association with immunodepression, the presence of other diseases was also searched among the 123 patients. An immunodepressive condition preceded the fungal disease in 25% of patients. Another associated disease commonly found in blastomycotic patients was diabetes mellitus (22%).
Blastomycosis is correctly suspected at the first clinical evaluation in only a small percentage of patients; pneumonia, cancer, and tuberculosis are the most common clinical considerations. Cutaneous involvement leads the clinician to the correct diagnosis in the majority of cases. One fourth of the patients with blastomycosis had underlying immunodepressive conditions, and underlying diabetes mellitus is present in 22% of patients.
The Epidemiology of Blastomycosis in Illinois and Factors Associated with Death.
Author(s) Mark S. Dworkin, Amy N. Duckro, Laurie Proia, Jeffery D. Semel, and
Greg Huhn. Clinical Infectious Diseases, volume 41 (2005), pages e107–e111
N Engl J Med. 1986 Feb 27;314(9):529-34.
Pulmonary blastomycosis: an appraisal of diagnostic techniques.
Martynowicz MA, Prakash UB. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Medical School and Mayo Medical Center, Rochester, MN 55905-0001, USA. Chest 2002 Mar;121(3):768-73 Abstract quote
OBJECTIVES: Pulmonary blastomycosis often mimics bacterial pneumonia or bronchogenic carcinoma, which may result in delayed therapy or the performance of unnecessary diagnostic procedures. We have reviewed the utilization of diagnostic techniques in the workup of patients with pulmonary blastomycosis, defined their diagnostic yields, and proposed an optimal diagnostic approach for the patient in whom pulmonary blastomycosis is considered. DESIGN: Retrospective chart review of all patients with the diagnosis of blastomycosis at a major academic medical center.
RESULTS: Of the 119 patients with blastomycosis, 56 (47%) had pulmonary involvement. A total of 92 specimens were obtained by noninvasive means (sputa, 72 specimens; tracheal secretions, 5 specimens; and gastric washings, 15 specimens) in 35 patients. KOH smears were prepared from 22 of those specimens (24%). The diagnostic yield from these culture specimens obtained by noninvasive means was 86% per patient, and 75% per single sample. The diagnostic yields from KOH smears were 46% and 36%, respectively. Flexible bronchoscopy was performed in 24 patients and yielded a diagnosis in 22 (92%). Cultures of bronchial secretions (19 patients) and BAL fluid (6 patients) were positive in 100% and 67% of patients, respectively. The corresponding yields of KOH preparations were 17% (1 of 6 preparations) and 50% (3 of 6 preparations), respectively. Pathology specimens including those from bronchoscopic lung biopsies (nine patients), bronchial brushings (two patients), and bronchoscopic needle aspiration (one patient) were positive in 22%, 50%, and 0% of cases, respectively. Cytology was usually performed to exclude malignancy and was positive for Blastomyces dermatitidis in five patients (sputum, three patients; bronchial washings, two patients). Thoracotomy was performed in 11 cases, and in all patients the procedure yielded a diagnosis. Serology results were available in 25 patients. Immunodiffusion was positive in 10 patients (40%), and complement fixation in 4 patients (16%).
CONCLUSIONS: In patients with pulmonary blastomycosis, the positive yield from respiratory specimen cultures is high, but the confirmation of a diagnosis may take up to 5 weeks. Wet smears and cytology examinations of respiratory specimens provide quicker diagnoses but are underutilized. Their routine use is recommended in endemic areas. Commonly used serologic assays are insensitive and are not useful for diagnostic screening.
Culture Sabouraud glucose agar, brain heart infusion agar, yeast-extract-phosphate agar, and a medium with cycloheximide, and then incubate at 30C. Grows best on the yeast extract agar or agar containing yeast extract such as Mould Inhibitory Agar (IMA) Mould form to yeast form conversion is necessary to ensure that the fungus suspected to be B. dermatitidis is not a similar fungus-accomplished by inoculating Kelley's agar or blood agar supplemented with glutamine and then incubating the inoculated tubes at 37C. Exoantigen technique and a DNA culture confirmation kit.
Practice Guidelines for the Management of Patients with Blastomycosis Stanley W. Chapman et al
Guidelines for the treatment of blastomycosis are presented; these guidelines are the consensus opinion of an expert panel representing the National Institute of Allergy and Infectious Diseases Mycoses Study Group and the Infectious Diseases Society of America. The clinical spectrum of blastomycosis is varied, including asymptomatic infection, acute or chronic pneumonia, and extrapulmonary disease. Most patients with blastomycosis will require therapy. Spontaneous cures may occur in some immunocompetent individuals with acute pulmonary blastomycosis. Thus, in a case of disease limited to the lungs, cure may have occurred before the diagnosis is made and without treatment; such a patient should be followed up closely for evidence of disease progression or dissemination. In contrast, all patients who are immunocompromised, have progressive pulmonary disease, or have extrapulmonary disease must be treated. Treatment options include amphotericin B, ketoconazole, itraconazole, and fluconazole. Amphotericin B is the treatment of choice for patients who are immunocompromised, have life-threatening or central nervous system (CNS) disease, or for whom azole treatment has failed. In addition, amphotericin B is the only drug approved for treating blastomycosis in pregnant women. The azoles are an equally effective and less toxic alternative to amphotericin B for treating immunocompetent patients with mild to moderate pulmonary or extrapulmonary disease, excluding CNS disease. Although there are no comparative trials, itraconazole appears more efficacious than either ketoconazole or fluconazole. Thus, itraconazole is the initial treatment of choice for non–life-threatening non-CNS blastomycosis.
April 2000. This guideline is part of a series of updated or new guidelines from the IDSA. Clinical Infectious Diseases 2000;30:679–83 q 2000 by the Infectious Diseases Society of America.
Blastomycosis: organ involvement and etiologic diagnosis. A review of 123 patients from Mississippi.
Lemos LB, Guo M, Baliga M. Cytopathology Service, Pathology Department, University of Mississippi Medical Center, Jackson, MS, USA. Ann Diagn Pathol 2000 Dec;4(6):391-406 Abstract quote
Blastomycosis can only be diagnosed through the identification of the yeasts of Blastomyces dermatitidis in body fluids, tissues, or cultured material. The charts from 123 patients treated for blastomycosis at the University of Mississippi Medical Center from January 1980 through May 2000 were reviewed to determine the role of wet preparation, cytology, histology, and culture in diagnosing this fungal disease. Cytology uncovered the etiologic agent in 56.1% of all cases and in 71.8% of pulmonary cases. Cytology also was the first method to disclose the fungus in 57.7% of pulmonary cases. Sputum was the cytology specimen examined in 51% of the patients. In 69 patients with lung involvement, pulmonary cytology was positive in 97% of cases. Wet preparation was the second method to most commonly uncover the fungus in 37.4% of all cases. Histology was the third method with 32.5% of positive cases. Cultures were positive in 64.2% of all cases but they were the first to detect the fungus in only 3.2% of all patients. There was pulmonary involvement in 87% of patients, cutaneous involvement in 20%, osseous involvement in 15%, and central nervous involvement in 3%. In the medical literature the relative proportion of pulmonary versus disseminated disease clearly increased in series reported after 1959.
Proportionally to the pattern of patients admitted to the University of Mississippi Medical Center, there is a clear predominance of black males among patients with blastomycosis followed by black females. White females constitute the sex/ethnic group least affected by this fungal disease.
Michael J.G. Harrison, DM, FRCP, Justin C. McArthur, MBBS, MPHInfect Med 15(7):474-478, 1998.
Blastomyces dermatitidis is a dimorphic yeast that is endemic in the south and south central US and in the Great Lakes area. Seeding of the CNS can occur after dissemination from a respiratory focus. Meningitis occurs in about 5% of cases, and mass lesions or blastomycomas can develop occasionally. CSF culture is rarely positive. An EIA using purified antigen A has a high sensitivity for blastomycosis and good specificity, and distinguishes blastomycosis from coccidioidomycosis. Experience is limited, but the recommended treatment at this time is intravenous amphotericin B, at least 2g.
Laryngeal blastomycosis: a commonly missed diagnosis.
Hanson JM, Spector G, El-Mofty SK. Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, USA. Ann Otol Rhinol Laryngol 2000 Mar;109(3):281-6
Blastomycosis is a relatively uncommon fungal disease that most commonly affects the lungs. Other organs may be involved, usually secondary to dissemination of the organism. Laryngeal blastomycosis may occur in isolation from active pulmonary disease. The signs, symptoms, clinical features, and pathological findings of laryngeal blastomycosis mimic those of squamous cell carcinoma. Misdiagnosis may result in inappropriate treatment with potential morbidity. Proper understanding of the clinical presentation and familiarity with the histopathologic features of this disease are therefore imperative. In this paper, we report 2 cases of laryngeal blastomycosis, 1 of which was misdiagnosed as squamous cell carcinoma, clinically and microscopically, with consequent radiotherapy and laryngectomy. In the other case, a clinical diagnosis of glottic squamous cell carcinoma was rendered. However, blastomycosis was identified in a biopsy specimen. We also review cases of isolated laryngeal blastomycosis that have been reported in the English-language literature during the last 80 years. A number of those cases were misdiagnosed clinically and microscopically as squamous cell carcinoma.
Perez-Lasala G, Nolan RL, Chapman SW, Achord JL. Division of Infectious Diseases, University of Mississippi Medical Center, Jackson. Am J Gastroenterol 1991 Mar;86(3):357-9 Abstract quote
Blastomycosis is a systemic fungal infection caused by Blastomyces dermatitidis. Involvement of the peritoneum is unusual, with only two previously reported cases that occurred in association with disseminated disease. A single case of histopathologically proven blastomycosis involving the peritoneum is presented, as well as a short overview of previously published cases on gastrointestinal and peritoneal blastomycosis. The case is unique in that chronic peritonitis was the only manifestation of disease. The diagnosis was made by laparoscopy.
Blastomycosis of the lumbar spine: case report and review of the literature,
with emphasis on diagnostic laboratory tools and management. Eur Spine J.
Giant forms of Blastomyces dermatitidis in the pulmonary lesions of blastomycosis.Potential confusion with Coccidioides immitis.
Watts JC, Chandler FW, Mihalov ML, Kammeyer PL, Armin AR.Department of Anatomic Pathology, William Beaumont Hospital, Royal Oak, Michigan 48072. Am J Clin Pathol 1990 Apr;93(4):575-8 Abstract quote
Typical yeast-phase cells of Blastomyces dermatitidis have a characteristic appearance in tissue sections. Fungal morphologic variation occurs infrequently in the lesions of blastomycosis, yet it can complicate the differential diagnosis, particularly if fresh tissue is not available for microbiologic culture. The authors report a case of pulmonary blastomycosis, confirmed by culture and direct immunofluorescence, in which some of the yeast-like cells were abnormally large. These giant yeast-like cells exceeded the size range accepted for the tissue forms of B. dermatitidis; therefore, coccidioidomycosis was considered initially in the differential diagnosis. Otherwise characteristic morphologic features of these cells, in particular multinucleation and the production of broad-based blastoconidia, helped resolve the differential diagnosis. The diagnosis can be confirmed by direct immunofluorescence or microbiologic culture.
Delayed diagnosis of osseous blastomycosis in two patients following environmental exposure in nonendemic areas.
Veligandla SR, Hinrichs SH, Rupp ME, Lien EA, Neff JR, Iwen PC.Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-6495, USA Am J Clin Pathol 2002 Oct;118(4):536-41 Abstract quote
Blastomycosis generally results from inhalation of Blastomyces dermatitidis conidia following exposure to contaminated soil in an endemic area. Primary infections commonly involve the lungs, although secondary dissemination to other body sites may occur. We describe 2 cases of osseous blastomycosis in people living outside the endemic areas. Both patients reported exposure to soil following injury to the knee from occupational activities. Mold isolated from each case was identified as B dermatitidis by micromorphologic characteristics including yeast conversion testing and by a positive AccuProbe Blastomyces dermatitidis test (GenProbe, San Diego, CA). Retrospective review of histologic slides, initially reported as negative, identified rare poorly staining, broad-based budding yeast forms in each case. Both patients were treated successfully with itraconazole with no evidence of recurrent infection after 1 year. These cases illustrate the importance of considering blastomycosis in the differential diagnosis of bony lesions, even though the patient may live outside an endemic area for B dermatitidis.
Blastomycosis: report of three cases from Alberta with a review of Canadian
cases. Mycopathologia. 1979 Aug 31;68(1):53-63
Blastomycosis in the Immunocompromised Host
Recent reports indicate that B. dermatitidis may infrequently act as an opportunistic pathogen, notably in patients who are in the late stages of AIDS, transplant recipients, and patients treated with immunosuppressive or cytotoxic chemotherapy [11, 20]. Disease in these patients is more aggressive and more often fatal than disease in the normal host. Pulmonary disease is more likely to present with diffuse pulmonary infiltrates and respiratory failure. Dissemination to multiple organs, including the CNS, also occurs more frequently. Mortality rates of 30%–40% have been reported, and most deaths attributed to blastomycosis occur during the first few weeks of therapy. Thus, early and aggressive treatment with amphotericin B (0.7–1 mg/ kg/d) is indicated for blastomycosis in the immunocompromised patient (AII). Most experts recommend a total dose of 1.5–2.5 g, although treatment for selected patients without CNS infection may be switched to itraconazole after clinical stabilization with amphotericin B (usually a minimum dose of 1 g)(BIII). Despite amphotericin B treatment, frequent relapses occur in patients with AIDS and in those patients who continue immunosuppressive therapy [11, 20]. Some authorities therefore recommend chronic suppressive therapy with an azole, preferably itraconazole, for those patients who respond to a primary course of amphotericin B treatment. Treatment with ketoconazole is discouraged because relapse rates are higher (DIII). Fluconazole treatment may be given special consideration for selected patients who have had CNS disease or patients unable to tolerate itraconazole owing to toxicity or drug interactions.
A profusion of fungi exists in the environment. Some fungi are able to cause an invasive infection in otherwise healthy individuals. Other fungi are opportunistic fungi that become invasive when immune defenses are compromised. Diagnosis of fungal infection is difficult. There are many problems when you try to connect a test result to a disease. Fungi are so abundant and there are so many varieties in every environment that it is seldom easy to pick just one cause among many. Fungi are inhaled and ingested. Foods always contain fungal spores and actively growing molds. Attempts to culture fungi often fail; only a small number grow in the culture media commonly used. Some new methods of detecting fungal DNA may be useful but development of reliable tests is slow and expensive.
'You are at Alpha Online, a service of Environmed Research Inc. Sechelt, British Columbia Canada. Orders for printed books, eBooks for download and nutrient formulas are placed at Alpha Online.
Secure Order Site
Order Alpha Education Books
Alpha Education Books: There are 20 books in this series that address important health issues and their solution. Everyone, who is interested in Nutritional Therapy, will need a copy of the Alpha Nutrition Program. All books can be downloaded as PDF files.
Click the add to cart buttons to begin your order for printed books for mail delivery to the USA and Canada. Click the Download buttons to order eBooks for download.
We ship through the Post Office to all destinations in Canada and the USA. All correspondence about your order is done by email- send to Alpha Support. All orders are completed with encrypted security. Payments are made through Pay Pal by account or credit cards.
Nutrient Formulas for Meal Replacement Alpha ENF
the complete nutrient set for meal replacement, nutrient supplementation and
food holidays. Alpha PMX performance mix,
the complete nutrient set except for fat with increased amino acids.
Alpha DMX the complete nutrient set except
for lipids ( fat) and carbohydrate... all vitamins, amino acids and minerals
Persona Digital publishes a series of books on current topics in psychology, sociology, neuroscience and philosophy. eBooks and can be downloaded to any destination on the planet. Printed books and eBooks are ordered from Alpha Online. Printed books are shipped only to Canada and the USA by postal services.
Nutritional Rescue Starter Packs Starter packs bundle books and formulas to help you get started solving your health problems. The starter packs are sold at discounts to make is easier and more affordable for you to learn more and try out a formula. A copy of the Alpha Nutrition Program is included in every starter pack. Starter Pack Details
Alpha Nutrition is a trademark and a division of Environmed Research Inc., founded in 1984 at Vancouver, BC, Canada. Online Since 1995. Experts in Self-Managed Care. Experts in Elemental Nutrient Formulas. We are located on the Sunshine Coast in Sechelt, a ferry ride from West Vancouver. Alpha Online can be reached using one of 2 URLS - www.nutramed.com or www.alphanutrition.com
PayPal is a secure payment gateway that authorizes credit card payment, usually within seconds of submitting your information. PayPal acts as a secure payment gateway for Visa, MasterCard, Discovery or AMEX credit cards. When your payment information is complete, you will receive an order confirmation email from PayPal and from Alpha Nutrition Online. We ship your order on the same or next business day.